These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC 62756-0073
Last updated: March 14, 2026
What is the drug associated with NDC 62756-0073?
NDC 62756-0073 is associated with Xyosted (testosterone enanthate), a testosterone replacement therapy approved by the FDA for adult males with primary or hypogonadotropic hypogonadism. It is delivered via a once-weekly injection administered subcutaneously.
Market Size and Demand Analysis
Current Market Landscape
The global androgen replacement therapy (ART) market was valued at approximately $1.2 billion in 2022.
The U.S. dominates this market, accounting for roughly 50%, driven by aging male populations and increased diagnosis of hypogonadism.
The incidence of hypogonadism in men aged 40-79 is estimated at 4-5%, with some studies reporting higher percentages.
The prevalence of hypogonadism is expected to grow with an aging demographic, projected to expand at a compound annual growth rate (CAGR) of 4-5% over the next five years.
Market Drivers
Increased awareness and diagnosis of low testosterone levels.
Shift toward more convenient administration routes, favoring injectables like Xyosted.
Market penetration by newer formulations offering fewer side effects or enhanced convenience.
Competitive Dynamics
Product Name
Formulation
Market Share (2022)
Price Range (per dose)
Launch Year
Xyosted
Testosterone enanthate
15%
$60-$80
2017
AndroGel
Topical gels
45%
$40-$70 (per gram)
2000
Testosterone Cypionate
Injectable
30%
$25-$50 (per mL)
1950s
Other generics
Various formulations
10%
$20-$60
Varies
Note: Xyosted faces competition mainly from topical gels and other injectables. Its market penetration remains limited compared to established therapies.
Off-Label and Alternative Treatments
Oral testosterone formulations are under development but face bioavailability challenges.
Novel delivery systems are being explored for better patient compliance and less injection discomfort.
Price Projections
Current Pricing Dynamics
Per dose cost (injectable): $60–$80
Monthly cost: $240–$320
Annual cost: $2,880–$3,840
Prices are influenced by factors such as:
Manufacturer pricing strategies.
Insurance reimbursement policies.
Contract negotiations with healthcare payers.
Future Price Trends (2023–2028)
Year
Estimated Price Range (per dose)
Factors Influencing Price
2023
$60–$80
Market competition, production costs, insurance negotiations
Projected prices are expected to decline approximately 5–10% annually driven by biosimilar entries and competitive market pressures.
Impact of Patent and Regulatory Changes
Xyosted’s patent protection is valid through 2027.
Patent expirations would enable biosimilar competition, likely reducing prices.
Price reductions could be as high as 20–30% upon biosimilar market entry.
Regulatory Landscape and Outlook
FDA approval for Xyosted was granted in 2017.
Pending biosimilar applications could reshape the market.
Regulatory pathways favoring biosimilars may accelerate entry, further pressuring pricing.
Key Market Trends and Risks
Growing preference for less invasive treatments may limit injectable market growth.
Cost containment initiatives by payers could restrict reimbursement levels.
Patent cliffs in late 2027 may precipitate significant price reductions due to biosimilar entry.
Key Takeaways
The testosterone replacement therapy market is expanding, with injectables like Xyosted holding a niche but competitive position.
The current price range is approximately $60–$80 per dose, translating to yearly costs nearing $3,840, contingent on dosing frequency.
Market growth is primarily driven by demographic trends and increased hypogonadism awareness.
Price projections indicate potential declines of 5–10% annually over the next five years, with accelerated reductions post-2027 due to biosimilar competition.
Frequently Asked Questions (FAQs)
When is Xyosted expected to face significant generic or biosimilar competition?
Patent expiration is projected for 2027, after which biosimilar entrants are likely.
How does the cost of Xyosted compare to other testosterone therapies?
It is generally more expensive than traditional injectables like testosterone cypionate and comparable to topical gels, with monthly costs around $240–$320.
Are there biosimilar versions of testosterone enanthate approved in the U.S.?
No biosimilars have been FDA-approved as of 2023, but several are under review or in development.
What factors influence pricing strategies for testosterone drugs?
Manufacturer strategies, insurance reimbursement policies, patent status, and competitive pressures.
What are the key risks to market growth?
Invasive administration preferences, regulatory shifts, biosimilar entry, and payer cost containment measures.
References
[1] MarketResearch.com. (2023). Global testosterone replacement therapy market report.
[2] U.S. Food and Drug Administration. (2017). FDA approval for Xyosted.
[3] IBISWorld. (2023). Hormone Replacement Therapy Industry in the US.
[4] WHO. (2022). Global prevalence of hypogonadism.
[5] IQVIA. (2022). Pharmaceutical pricing and reimbursement data.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
